Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Systech International Adds Distinguished Members to its Board

Published: Tuesday, February 12, 2013
Last Updated: Tuesday, February 12, 2013
Bookmark and Share
Systech International announces the addition of John Bailye and Michael Fawkes to its Board of Directors.

Robert DeJean, President and CEO, Systech International said: “We are delighted to welcome new members to our Board, John Bailye and Michael Fawkes, who bring a vast amount of industry experience and business acumen upon which Systech will draw as we continue to grow.”

John Bailye is a globally accomplished entrepreneur with a resume that runs the gamut from start-ups to proven operational management and strategic leadership in mid to large sized companies. John’s successes reflect a passion for focusing on his customers, both as a source of product direction and, as the ultimate arbiter of his companies’ success.

In a career covering strategic consulting services; leading edge global technology development and deployment and; of late, specialty pharmaceuticals, he has consistently demonstrated his ability to build great management teams and deliver outstanding returns to shareholders. In John’s penultimate role, he guided, developed and grew Dendrite International from a two-person startup company to a complex global business entity over a period of 20 years. Dendrite had $750 million in market capitalized value, over $450 million in annual sales with high profitability, and more than 3000 employees in over 25 countries.

John Bailye said: “I am honored to join Systech’s Board of Directors. As a market leader with innovative technology in a rapidly growing market and new senior management additions, Systech is poised for significant growth. The company is thriving and I’m eager to help shape the organizational direction over the coming months and years.”

Michael Fawkes brings more than 30 years of experience to the Systech Board. Currently he serves as an Independent Director for Saba Software, a NASDAQ listed company, as well as several private technology companies.

From February 2008 through January 2012, Michael served as an Operating Partner with Vantage Point Capital Partners, a leading global investor in energy innovation and efficiency, information technology and healthcare.

Prior to joining Vantage Point Capital Partners, Michael spent 29 years at Hewlett-Packard Company, a leading global provider of products, technologies, software, solutions and services to individuals and businesses, serving in various executive roles in operations and finance, including Senior Vice President of Operations for HP’s Imaging and Printing business. Prior to joining HP, Michael was a CPA with Arthur Andersen. Michael holds a B.B.A. and a M.A. in Finance from the University of Iowa.

Michael Fawkes said: “Systech is positioned very well to make a critical contribution to patient safety as it helps its customers combat counterfeiting in the Pharmaceutical market. Additionally, Systech has a tremendous opportunity to advance its offering to other markets. I am thrilled to have the opportunity to work with Systech as its scales for the future.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Unique Visual Stimulation May Be New Treatment for Alzheimer’s
Noninvasive technique reduces beta amyloid plaques in mouse models of Alzheimer’s disease.
Major Neuroscience Initiative Launched
Tianqiao and Chrissy Chen Institute invest $115 million to further expand neuroscience research, while Caltech construct $200 million biosciences complex.
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!